Advanced Accelerator Applications
Advanced Accelerator Applications
Explore linked clinical trials.11 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| 177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 2 | 2026-06-05 | NCT04529044 | |
| Radiopharmaceutical Treatment of Advanced Kidney Cancer | Clear-cell metastatic renal cell carcinoma, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, kidney cancer, kidney disorder, neoplasm, urinary system disorder | Recruiting | Phase 2 | 2026-06-04 | NCT06783348 | |
| Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor | Active, not recruiting | Phase 1 | 2026-04-13 | NCT05249114 | |
| Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, digestive system neuroendocrine neoplasm, neoplasm, neuroendocrine neoplasm, paraganglioma, pheochromocytoma, primitive neuroectodermal tumor | Active, not recruiting | Phase 2 | 2026-02-12 | NCT04711135 | |
| Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET | digestive system neuroendocrine neoplasm | Active, not recruiting | Phase 3 | 2026-01-21 | NCT03972488 | |
| Post-Authorization Long-Term Safety Study of LUTATHERA | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor | Active, not recruiting | Not stated | 2025-12-23 | NCT03691064 | |
| Lutathera and ASTX727 in Neuroendocrine Tumours | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor | Recruiting | Phase 1 | 2025-11-24 | NCT05178693 | |
| Feasibility and Impact of Liquid Biopsy Genomic Profiling on Treatment Patients With Metastatic Prostate Cancer in Spain (SOLTI-2102) | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, metastatic prostate carcinoma, neoplasm, prostate cancer, prostate disorder | Recruiting | Not stated | 2025-08-06 | NCT05885009 | |
| Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Metastases | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor | Recruiting | Phase 2 | 2025-07-23 | NCT04837885 | |
| In Men With Metastatic Prostate Cancer, What is the Safety and Benefit of Lutetium-177 PSMA Radionuclide Treatment in Addition to Chemotherapy | Metastatic Hormone Naive Prostate Cancer | Active, not recruiting | Phase 2 | 2025-07-11 | NCT04343885 | |
| 177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Primitive, Peripheral, epithelial neoplasm, neoplasm, neuroblastoma, neuroepithelial neoplasm, primitive neuroectodermal tumor | Recruiting | Phase 2 | 2025-02-11 | NCT04903899 |